

January 10, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of a patent grant for anti-RAMP2 antibodies which inhibit the formation of new blood vessels with a new mechanism

Tokyo, January 10, 2023 – Kidswell Bio Corporation (KWB) is delighted to announce that KWB has received a patent grant from Japan Patent Office for anti-RAMP2 antibodies (RAMP: Receptor Activity-Modifying Protein, KWB project code: GND-004), which is one of candidates for a breakthrough new antibody drug that inhibits the formation of new blood vessels with a new mechanism.

KWB has been collaborating with Professor Takayuki Shindo, School of Medicine, Shinsyu University and successfully created anti-RAMP2 antibodies. RAMP2 is a receptor activity-regulating protein that transmits angiogenesis signals into cells by binding to adrenomedullin, a vasodilator peptide. As anti-RAMP2 antibodies block RAMP2 activity, KWB expects that anti-RAMP2 antibodies can be new therapeutic antibodies for diseases with pathological angiogenesis such as retinopathy of prematurity. Especially, as the signaling pathway of formation of new blood vessels related to this RAMP2 is different from the VEGF pathway targeted by an existing medicine, KWB believes that anti-RAMP2 antibodies have a high possibility of therapeutic effects for both patients who have not been treated well with currently available anti-VEGF drugs and have relapsed after using the anti-VEGF drugs.

The financial impact on the business results for the fiscal year ending March 2023 is expected to be minimal.

Outline of the patent

Name of the Invention: Anti-RAMP2 antibodies

Patent Number: 7202011

Patentee: Kidswell Bio Corporation

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com